Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by gainwidpatienceon Jun 22, 2018 11:29pm
141 Views
Post# 28217384

RE:Is chop zone

RE:Is chop zoneYes. It’s a pump and dump for those who did NOT do research on iCo-019 (Oral Amphotericin 
Read the bold one - Lot of people just buying and selling because of volume and trading action. No one knows how big it is once the NR comes in July 1st week  You will scratch your head when the SP is $3 :) at July end!!


iCo Therapeutics, Inc. (ICOTF)

TheMicrocapNews, Wall St Report, OTC Markets Group, and Vantage Wirereported earlier on iCo Therapeutics, Inc.(ICOTF), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

iCo Therapeutics, Inc. identifies existing development stage assets for use in underserved ocular and infectious diseases. The Company owns the international exclusive rights to an oral delivery system - Amphotericin B (Amp B) - for life-threatening infections. Amphotericin B is the gold standard for systemic antifungal drugs. It is one example of a well-established, highly efficacious systemic antifungal drug that has a 50-year history of intravenous therapy.

<< Previous
Bullboard Posts
Next >>